April 2, 2020 09:00 ET | Source: FemPulse
SAN FRANCISCO, April 2, 2020 — FemPulse Corporation, a private, clinical-stage bioelectronic medicine company, developing a novel wearable bioelectronic device for the personalized treatment of medical conditions in women, today announced that Robert Taub will join the Company’s board of directors as the representative of the Series B investors.
Mr. Taub is the founder and Executive Chairman of Nyxoah (Nasdaq: NYXH), which is developing neurostimulation therapy for sleep disordered breathing conditions, as well as the Chief Executive Officer of Man & Science, which is developing neurostimulation therapy for headache disorders. He is a serial life science entrepreneur, who co-founded Octapharma, founded and managed Omrix Biopharmaceuticals through a Nasdaq IPO and acquisition by J&J, and became the lead investor in Neuroderm, where he served as Chairman through its Nasdaq IPO and sale to Mitsubishi-Tanabe.
Mr. Taub joins outside directors Darrin Uecker, CEO of bioelectronics company Pulse Biosciences (Nasdaq: PLSE), and Flip Gianos, former Managing Partner of leading information technology and healthcare venture capital firm InterWest Partners, on the FemPulse board.
FemPulse recently closed its Series B financing, to accelerate completion of the Company’s wireless wearable bioelectronic device and its pivotal clinical trial for regulatory clearance. “We are delighted to have a medtech entrepreneur with such a record of success represent our Series B investors. Robert and a number of our other Series B industry investors are based in Europe, which will be especially valuable as we pursue European CE Marking with FemPulse GmbH in Vienna,” commented Peter Fredericks, FemPulse Chairman.
The Series B financing came as FemPulse was successfully completing its EVANESCE-OAB, prospective, randomized, sham-controlled clinical study evaluating the safety and performance of the FemPulse device in an at-home and at-work setting. “The successful completion first of our in-clinic trial, with results presented at an American Urological Association annual conference, and now of our EVANESCE-OAB at-home trial, with results again to be presented at an AUA annual meeting, lead to our oversubscribed financing,” added Dr. Alexandra Haessler, founder and Chief Medical Officer. “I am grateful for Robert’s strong support in helping realize the FemPulse vision of our wearable bioelectronic device as a first option for treating the 17% of women suffering from OAB, as well as sensing data and providing therapy for other widespread medical conditions where medications have limited efficacy and/or side-effects.”
“I look forward to helping realize FemPulse’s great potential,” said Mr. Taub, “FemPulse’s patented, wearable neuromodulation device is a real game-changer, making the benefits of bioelectronic medicine accessible to all women worldwide.”
About FemPulse Corporation
FemPulse Corporation is a privately held clinical-stage bioelectronic medicine company developing a novel wearable bioelectronic platform for the personalized treatment of medical conditions in women. FemPulse’s vaginally-inserted, wearable neuromodulation device is intended to provide mild electrical nerve stimulation as an alternative to pharmaceutical medications. The device is designed to sense and collect data, as well as to communicate with a patient’s smartphone and their physician. The initial application is to treat the one in six women worldwide suffering from overactive bladder (OAB). For more information, visit www.fempulse.com.
Peter Fredericks, Chairman